Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ-1,99
KB0,90
PKN65,1765,192,29
Msft420,9420,94-0,11
Nokia3,2953,299-0,91
IBM190,66190,69-0,07
Mercedes-Benz Group AG73,973,920,53
PFE27,8727,880,34
28.03.2024 16:42:11
Indexy online
AD Index online
select
AD Index online
 

  • 28.03.2024 16:27:08
Psychemedics (NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
2,95 -1,67 -0,05 1 255
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 28.03.2024
Popis společnosti
Obecné informace
Název společnostiPsychemedics Corp.
TickerPMD
Kmenové akcie:Ordinary Shares
RICPMD.O
ISIN-
Poslední známé roční výsledky31.12.2022
Poslední známé čtvrtletní výsledky30.09.2023
Počet zaměstnanců k 31.12.2022 133
Akcie v oběhu k 06.11.2023 5 801 761
MěnaUSD
Kontaktní informace
Ulice125 Nagog Park Ste 200
MěstoACTON
PSČ01720-3451
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon19 782 068 220
Fax13026365454

Business Summary: Psychemedics Corporation is a hair drug testing company. The Company provides testing services for the detection of drugs of abuse through the analysis of hair samples. Its testing methods utilize a patented technology that digests the hair and releases drugs trapped in the hair without destroying the drugs. The Company customizes its enzyme immunoassay (EIA) procedures to drug test hair samples. It provides screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, phenylcyclohexyl piperidine (PCP), amphetamines (including ecstasy, eve, and Adderall), opiates (including heroin, hydrocodone, hydromorphone, oxycodone and codeine), synthetic cannabinoids (including K2, Spice, Blaze), benzodiazepines (Xanax, Valium, and Ativan), nicotine, Fentanyl, and alcohol. The Company markets its corporate drug testing services through its own sales force, distributors, and webinars. It markets its home drug testing service, PDT-90, through the Internet.
Financial Summary: BRIEF: For the nine months ended 30 September 2023, Psychemedics Corp. revenues decreased 12% to $17.1M. Net loss increased from $396K to $3.2M. Revenues reflect Testing segment decrease of 14% to $14.4M, Shipping Collection Hair segment decrease of 3% to $2.6M. Higher net loss reflects General & Administrative increase of 21% to $5.3M (expense), Settlement increase from $0K to $500K (expense). Dividend per share remained flat at $0.14.
Odvětvová klasifikace
TRBC2009Healthcare Facilities / Services
TRBC2012Medical & Diagnostic Laboratories
RBSS2004Healthcare Facilities
MGINDUSTRYHealthcare Facilities
MGSECTORHealthcare
NAICSMedical Laboratories
NAICS2007Medical Laboratories
NAICS1997Medical Laboratories
SICMedical Laboratories
SICMedical Laboratories



  • Poslední aktualizace: 28.03.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorBrian Hullinger5617.08.202317.08.2023
Vice President - Finance, TreasurerDaniella Mehalik3327.11.202327.11.2023
Chief Revenue OfficerShannon Shoemaker-21.09.202321.09.2023